Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Esperion (ESPR) Announces Initiation Of Phase 3 Clinical Program With Long-Term Safety And Tolerabil

Wednesday, January 13, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

— Company to Provide Details of Phase 3 Global Development Strategy in Q2 2016 —

ANN ARBOR, Mich., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced the start of a global Phase 3 long-term safety and tolerability study (ETC-1002-040) of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. This study will enable the Company to understand the 52 week safety profile of bempedoic acid, and top-line results are expected in the fourth quarter of 2017.


Read More

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal